News - Biotechnology


Current filters:


Popular Filters

2001 to 2025 of 2107 results

Actelion's selective S1P1 receptor agonist ponesimod to go into Phase III MS trial


Switzerland’s Actelion (SIX: ATLN) said this morning that the primary endpoint - reduction in the…


Amgen 2nd-qtr 2011 profits down but still top analysts estimates


The world’s largest biotechnology company, USA-based Amgen (Nasdaq: AMGN) has reported second-quarter…


Celgene 2nd-qtr 2011 boosted by Revlimid and Vidaza


US biotech firm Celgene (NasdaqGS: CELG) has presented strong second-quarter 2011 results, with adjusted…


Amylin and Eli Lilly submit CRL reply on Bydureon to US FDA


US biotech Amylin Pharmaceuticals (Nasdaq: AMLN), drug major Eli Lilly (NYSE: LLY) and partner Alkermes…

AlkermesAmylinBiotechnologyBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

US biotech companies reduce R&D spend, maintain cash reserves, BDO USA study finds


R&D expenditures in the US biotechnology industry have declined for the second straight year as companies…

BiotechnologyFinancialNorth AmericaResearch

The pros and cons of Malaysia pharmaceuticals market assessed


The key attractions of the Malaysian pharmaceutical market over the longer term are the government's…

Asia-PacificBiotechnologyHealthcareMarkets & MarketingPharmaceutical

Biogen Idec posts 28% rise in Tysabri sales for 2nd-qtr 2011


USA-based biotechnology company Biogen Idec (Nasdaq: BIIB) announced its second quarter 2011 results,…

Biogen IdecBiotechnologyFinancial

Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales


US biotech Amylin Pharmaceuticals (Nasdaq: AMLN) saw its shares all 4.9% to $12.65 after it reported…


US FDA unit CDER develops strategic science and research agenda


A US Food and Drug Administration report from its Center for Drug Evaluation and Research (CDER), made…

BiotechnologyNorth AmericaPharmaceuticalRegulationResearch

Actelion reports bigger-than-expected 2nd-qtr 2011 loss


Switzerland-based Actelion (ATLN: VX) reported first-half 2011 results with 8% (local currency) growth…


AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco


US drugmakers AMAG Pharmaceuticals (Nasdaq: AMAG) and Allos Therapeutics (Nasdaq: ALTH) entered into…

Allos TherapeuticsAMAG PharmaceuticalsBiotechnologyMergers & AcquisitionsPharmaceutical

Cellectis and Lonza achieve significant milestone on CHO-K1SV GS knock-out


Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of French biotech…


Optimism for US biotech, but developmental drugs draw scrutiny from FDA


There is plenty of optimism surrounding the US biotechnology industry as firmer pricing and new products…

AVI BioPharmaBioSante PharmaceuticalsBiotechnologyNorth AmericaOncologyRegulationResearch

Major changes at US FDA, with new posts and appointments


The world of FDA regulation is changing rapidly and, in an effort to keep current, US Food and Drug Administration…

BiotechnologyGenericsManagementNorth AmericaPharmaceuticalRegulation

Room for improvement of HTA process to accelerate medicines access


A new report on Health Technology Assessment (HTA) processes published today highlights significant areas…

Asia-PacificBiotechnologyEuropeNorth AmericaPharmaceuticalRegulation

Report highlights urgent need for rethink on biopharma industry innovation


Life sciences companies with “very effective” innovation programs typically produce twice as…

BiotechnologyMarkets & MarketingPharmaceuticalResearch

Biopharmaceutical sector’s impact on US economy and jobs demonstrated


“At a time when the USA is facing a jobs crisis, evidenced by the terrible employment numbers from…

BiotechnologyHealthcareNorth AmericaPharmaceuticalPoliticsPricing

Amgen in up to 695 million-euro BiTE antibody deal with Micromet


US drug discovery firm Micromet (Nasdaq: MITI) stands to earns as much as 695 million euros ($991 million)…


US Nevada state judge denies Roche and Genentech motions to dismiss PDL BioPharma's royalties complaint


The Second Judicial District Court of US state Nevada ruled in favor of PD BioPharma (Nasdaq: PDLI) on…

BiotechnologyGenentechLegalNorth AmericaOncologyPDL BioPharmaPharmaceuticalRoche

Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq


French drug major Sanofi (Euronext: SAN) and its US biotech subsidiary Genzyme have announced mixed top-line…


Biopharma should be part of transatlantic trade and economic discussions, Lilly CEO urges


John Lechleiter, chairman, president and chief executive of US drugs major Eli Lilly (NYSE: LSE) has…

BiotechnologyEli LillyEuropeMarkets & MarketingNorth AmericaPharmaceuticalPoliticsRegulation

China’s monoclonal antibody industry growing but still lagging USA and Europe


China has been engaging in monoclonal antibody R&D for some time, but still lags far behind European…

Asia-PacificBiotechnologyMarkets & MarketingMerck KGaAOncologyPharmaceuticalRoche

HUYA Bioscience and Biolake collaborate to boost China’s pharma innovation platform


San Diego, USA-headquartered HUYA Bioscience International, a leader in globalizing China’s pharmaceutical…

Asia-PacificBiolakeBiotechnologyHUYA BiscienceLicensingPharmaceuticalResearch

Bristol-Myers Squibb in up to $465 million deal with Innate Pharma for cancer antibody


US drug major Bristol-Myers Squibb (NYSE: BMY) has signed a global agreement with French biotech firm…

BiotechnologyBristol-Myers SquibbInnate PharmaLicensingOncologyPharmaceutical

2001 to 2025 of 2107 results

Back to top